SELLING PEPTIDES IN THE UK: LEGAL, REGULATORY AND COMPLIANCE CONSIDERATIONS
Natalia Constantine, together with Lucie Tauveron of Culbert Ellis, examine in a co-authored article how UK rules apply to the sale, advertising and import of peptides, and the potential consequences where a product falls within the medicines framework, including MHRA enforcement and POCA-related recovery.
Can you legally sell peptides in the UK simply because they are labelled “for research use only”? Not necessarily.
The legal position can change depending on what the peptide is, what it is intended to be used for, and how it is described and marketed to customers. This is where businesses can run into difficulty, particularly where a product is promoted for purposes such as weight loss, muscle growth, recovery or aesthetic treatment.
The Medicines and Healthcare products Regulatory Agency (MHRA), the UK regulator responsible for medicines and certain other healthcare products, looks at the substance itself as well as the way it is presented and promoted when considering whether it falls within the medicine’s regulatory framework. As a result, a peptide that appears to be a straightforward research product may raise very different legal issues if it is marketed inappropriately.
Peptides occupy a regulatory grey area, and businesses that misjudge it face real risk. This article explains when a peptide becomes a medicinal product, why “research use only” labelling may not protect you, what aesthetic clinics need to watch for, and what happens when the regulatory position is wrong.
What Are Peptides?
Peptides are short chains of amino acids, the building blocks of proteins. They occur naturally in the body andplay a part in a range of biological processes. Synthetic peptides are also manufactured for a variety of purposes, from scientific research to potential medical, aesthetic and wellness uses .
The term “peptide” covers a wide range of substances with different properties, functions and potential uses. Importantly, the fact that something is a a peptide does not determine its legal status. That depends on the particular peptide, its intended purpose, and how it is supplied, presented or marketed. Some peptides commonly encountered in the UK market include BPC-157, TB-500, CJC-1295, Ipamorelin, GHK-Cu, Semax and Melanotan II. These substances are not interchangeable and may have very different uses and regulatory considerations. For example, some are the subject of scientific research into potential therapeutic applications, while others are marketed for purposes relating to aesthetics, fitness or research. Businesses involved in the manufacture, import, sale or use of peptide products should therefore assess the legal status of each individual product rather than treating “peptides” as a single regulatory category.
Did you know? 1,240 research peptide ads were identified by the ASA in a four-week UK monitoring exercise in 2026. Of those reviewed, 43% were rated high compliance risk, while the remaining 57% were rated medium risk.
Are Peptides Legal in the UK?
Peptides are not, as a category, illegal in the UK. Their legal status depends on the specific peptide, its intended use and the way in which it is presented, marketed or supplied. Under the Human Medicines Regulations 2012, a product may be a medicinal product if it is presented as treating or preventing disease, or if it is used to modify a physiological function through a pharmacological, immunological or metabolic action.
Where a peptide falls within this definition, it will generally need the appropriate authorisation before it can lawfully be sold or supplied in the UK. Regulation 46 provides that an unauthorised medicinal product cannot be sold, supplied or offered for sale or supply, subject to specific exceptions.
This means that the legality of a peptide cannot be determined simply by its name or by the fact that it is being sold by other businesses. A product’s intended purpose, claims, labelling, packaging, and advertising may all be relevant when determining its regulatory status. For businesses operating in the peptide market, it is therefore important to assess each product on its individual circumstances rather than assuming that all peptides are subject to the same rules.
Did you know? In May 2026, the MHRA made its largest-ever seizure of unlicensed weight-loss medicines, recovering around 12,000 doses from a site in Northamptonshire where peptide products were also being manufactured and distributed.
Can You Sell Peptides in the UK?
Whether you can legally sell peptides in the UK depends on the specific product and how it is being sold. There is no general prohibition on selling all peptide products. However, where a peptide is classified as a medicinal product, the Human Medicines Regulations 2012 prohibit it from being sold, supplied or offered for sale or supply without the appropriate authorisation.
This is particularly important because the way a product is presented, advertised and marketed can be relevant to whether it is considered a medicinal product. Claims made on a website, product packaging, social media or other promotional material will be taken into account. The MHRA specifically considers a product’s claims, wording, graphics and intended use when assessing its regulatory status.
As a result, businesses should not assume that a peptide can be legally sold simply because it is available from other suppliers or labelled “research use only”. The regulatory position should be assessed on a product-by-product basis, taking into account its intended purpose and the way it is supplied and marketed.
A real life example:
Retatrutide is a peptide being investigated for weight management. It is not currently authorised in the UK. The MHRA has warned that because it is still in clinical trials, any supplies found in the UK are likely to be illegal and potentially dangerous to health.
The MHRA has also acted on that warning. In October 2025 its Criminal Enforcement Unit raided an illicit manufacturing facility in Northampton, seizing tens of thousands of empty pens, raw chemical ingredients and more than 2,000 unlicensed retatrutide and tirzepatide pens awaiting dispatch to customers. Further raids followed in Lincolnshire, Nottinghamshire and Northamptonshire, with thousands more doses seized.
When Is a Peptide a Medicinal Product?
Under UK law, the classification will depend on what the product is and how it is presented and used. A peptide is more likely to fall within the definition of a medicinal product where it is marketed as treating or preventing a disease, or where it is intended to have a pharmacological, immunological or metabolic effect on the body. The way a product is described can therefore be important. Claims made on a website, product packaging, social media or other advertising may all be taken into account when determining its status.
For example, a peptide described as helping to heal injuries, reduce inflammation or treat a medical condition is more likely to attract scrutiny than one sold genuinely for laboratory research. Businesses should also be careful about relying on terms such as “research use only”, as the label alone will not determine the legal position if the product is, in practice, being supplied for use by humans.
Does “Research Use Only” Make Peptides Legal?
No. Simply labelling a peptide “research use only” (RUO) does not automatically make its sale or supply lawful in the UK. The MHRA looks at the product as a whole, including its intended purpose, claims, labelling, packaging, advertising and how it is actually being marketed. A disclaimer may therefore carry little weight if the surrounding material suggests that the product is intended for human use. The MHRA has specifically noted that disclaimers do not override medical claims made elsewhere in product literature, websites or advertising.
For example, describing a peptide as “for research only” while a website also promotes it as helping with muscle growth, weight loss, recovery or the treatment of a condition could raise questions about whether it is in fact being supplied for a medicinal purpose. Businesses should therefore treat “research use only” as a label, not a regulatory exemption, and consider the full circumstances in which the product is being supplied and marketed.
Can Aesthetic Clinics Use Peptides?
Aesthetic clinics need to be careful when using peptides in treatments. There is no general rule preventing clinics from using all types of peptides, but where a peptide is considered a medicinal product, the relevant medicines regulations will apply. This is particularly important for injectable peptides marketed for purposes such as skin rejuvenation, fat loss, muscle recovery or other aesthetic outcomes. A clinic cannot simply purchase a peptide from a supplier and administer it to clients because it is commonly used within the aesthetics industry. The clinic should first establish the regulatory status of the particular product, whether it has the necessary authorisation, and whether the person prescribing or administering it is legally permitted to do so. Where a product is unauthorised or supplied outside the applicable medicine’s framework, both the supplier and the clinic may face regulatory and legal consequences.
Advertising Peptides: What Is Permitted?
Advertising is another area where peptide businesses need to be particularly careful. If a peptide is considered a medicinal product, strict rules apply to how it can be promoted.
In Great Britain, an advertisement cannot be published for a medicinal product unless the product has the appropriate authorisation, and prescription-only medicines cannot be advertised to the general public. Advertising must also be accurate and not misleading, and businesses cannot make claims that go beyond the product’s authorised uses or suggest that its effects are guaranteed. This means that claims made on a website, Instagram page, product listing or other promotional material can create regulatory issues, particularly where a peptide is marketed as helping with weight loss, muscle growth, recovery, anti-ageing or the treatment of a medical condition.
Example: A useful way to understand the rules is to look at how an advertisement would be viewed in practice. Imagine a peptide business posts on Instagram: “New peptide for weight loss – lose 10kg in 8 weeks. Order now.” Even if the product is described elsewhere on the website as “research use only”, those claims could raise serious regulatory concerns because they suggest the product is intended for human use and for treating or modifying a physiological condition. MHRA and the Advertising Standards Authority (ASA) look at the overall impression created by advertising, rather than simply the disclaimer attached to a product.
This is particularly relevant online: in 2025, the ASA and MHRA issued a joint enforcement notice making clear that prescription-only weight-loss medicines must not be advertised to the public, including through social media and influencers. So, would the example above be allowed? The answer is likely no, where the product is an unauthorised or prescription-only medicinal product. This is why businesses should review not only the wording of their advertisements, but also their websites, social media posts, images, hashtags and any other material that could indicate the intended use of the peptide.
Importing Peptides Into the UK
Importing peptides into the UK is not simply a matter of ordering products from an overseas supplier and having them delivered to a UK address. The first question is whether the peptide is considered a medicinal product, as this can trigger specific licensing and import requirements. Where a peptide is a medicinal product, businesses importing it into Great Britain may need a manufacturer’s licence or wholesale distribution licence, depending on the circumstances and where the product is being imported from. Unlicensed medicinal products are subject to additional requirements, including notification to the MHRA, and only appropriately licensed importers can submit that notification.
The position can also differ between Great Britain and Northern Ireland, so businesses should consider where the product is being imported and how it will subsequently be supplied. For peptide businesses, checking the regulatory status of the product before placing an overseas order is therefore an important part of the compliance process.
Who Regulates Peptides?
There is not one single regulator responsible for every peptide product in the UK. The MHRA is the main regulator where a peptide falls within the medicine’s framework. It is responsible for regulating medicines and can investigate products that may be unauthorised or incorrectly marketed as something other than a medicine.
Advertising is a separate but closely related issue. The ASA oversees advertising under the UK advertising codes, including online advertising and social media. Where a peptide is a medicinal product, its advertising must comply with the relevant rules, and prescription-only medicines cannot be advertised to the public. Depending on the product and how it is used, other regulators may also be relevant, such as the Care Quality Commission (CQC) for certain regulated healthcare activities.
What Happens If Peptide Regulations Are Breached?
Breaching peptide regulations can have consequences that go beyond a fine or prosecution. Where a peptide is an unauthorised medicinal product, selling, supplying or offering it for sale can amount to a criminal offence under the Human Medicines Regulations 2012, with serious penalties including an unlimited fine and, in some circumstances, imprisonment. Regulatory authorities can also investigate businesses, seize products and take enforcement action.
There is also a potential Proceeds of Crime Act 2002 (POCA) angle. Where money or other assets are considered to have been obtained through unlawful conduct, the authorities can pursue civil recovery, including through the High Court, to recover property representing the proceeds of that conduct. Importantly, civil recovery does not require a criminal conviction; the authorities generally need to establish, on the balance of probabilities, that the property was obtained through unlawful conduct. For a peptide business, this could therefore mean that the financial consequences extend beyond the individual products being seized and potentially include profits or other assets linked to unlawful sales.
The consequences of getting it wrong can go well beyond a fine. If a peptide is an unauthorised medicinal product, selling, supplying or offering it for sale is a criminal offence under the Human Medicines Regulations 2012. On conviction in the Crown Court, the penalty is an unlimited fine, up to two years’ imprisonment, or both. Unlawful advertising carries similar penalties. The MHRA can also investigate, seize products and take further enforcement action.
There is also a Proceeds of Crime Act 2002 dimension. If money or other assets are believed to derive from unlawful conduct, the authorities can bring civil recovery proceedings in the High Court to recover them. No criminal conviction is needed: the authorities only have to show, on the balance of probabilities, that the property was obtained through unlawful conduct. Authorities may also seize cash, obtain account freezing orders and, following a conviction, seek a confiscation order. For a peptide business, this means the financial exposure may extend well beyond seized stock, to the profits and other assets linked to unlawful sales.
How Can Peptide Businesses Reduce Regulatory Risk?
The easiest way to reduce regulatory risk is to check the position before selling a peptide, rather than after a problem arises. Businesses should start by identifying exactly what you are selling, how you are selling and to whom. This will allow you to assess whether it could be classed as a medicinal product.
Next, review how the product is described across the business, including the packaging, website, social media and advertising. Claims about weight loss, muscle growth, recovery, anti-ageing or treating a medical condition can all create regulatory issues.
Businesses should also check whether you need a licence to manufacture, import or supply the product, and make sure their suppliers are reputable and properly authorised. Where the position is unclear, obtaining legal advice or seeking guidance from the MHRA can help address issues before the product reaches the market.
In practice, it comes down to three simple rules: check the product, check the claims and check the supply chain.
Peptide Compliance: A Practical Checklist
Think your peptide business is compliant? Before putting a product on the market, run through the questions below.
A “yes” to each does not guarantee compliance, but a “no” or “not sure” is a good reason to take a closer look.
What exactly are you selling?
Have you identified the specific peptide and what it contains?
Have you checked whether it could fall within the definition of a medicinal product?
What are you saying about it?
Have you reviewed your website, product listings, packaging and social media?
Are you making claims about weight loss, muscle growth, recovery, anti-ageing or treating a medical condition?
Does your marketing suggest that the product is intended for use by people?
Does “research use only” actually reflect reality?
Is the product genuinely being supplied for research purposes?
Does anything else on your website or social media contradict that?
Are you relying on the wording “research use only” as your main defence?
Are you allowed to supply it?
If the product is a medicinal product, does it have the required marketing authorisation?
Do you hold any licences required for manufacturing, importing or wholesaling?
Have you checked the position with your suppliers?
Could a regulator see your business differently?
Would the Medicines and Healthcare products Regulatory Agency (MHRA) consider your product a medicinal product based on how it is presented?
Have you obtained specialist advice where the legal position is unclear?
The golden rule: do not just look at the label on the vial. Look at the whole picture: the product, the claims, the customer, the intended use and the way it is being sold. That is where many of the regulatory risks arise.
For more information on our Regulatory and Professional Discipline practice, please click here.